Indeed, our data suggest that a combined therapy targeting both DPP4 and YAP1 in FAP+ CAF might be necessary to fully suppress the emergence of the immunosuppressive ECM-myCAF and TGFβ-myCAF clusters and therefore improve response to immunotherapies in BC patients. The gene discussed is TGFB1; the disease is breast cancer.